GlassScriptPhysician profile
Amanda N Elswick
NPI 1720897705
$583.88
in general payments reported to CMS, 2019-2025
14 companies · $584 in 2025
The $584 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $584.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $584.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $583.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $223.71 | 2025 | |
| Amgen INC. | $60.73 | 2025 | Evenity |
| Pfizer INC. | $52.56 | 2025 | |
| Collegium Pharmaceutical, INC. | $33.45 | 2025 | Jornay Pm |
| Abbott Laboratories | $32.51 | 2025 | Freestyle Libre |
| Exact Sciences Corporation | $31.04 | 2025 | Cologuard Collection Kit |
| Alexion Pharmaceuticals, INC. | $23.79 | 2025 | Ultomiris |
| Axsome Therapeutics, INC. | $21.14 | 2025 | Symbravo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.03 | 2025 | Xifaxan |
| Boston Scientific Corporation | $19.53 | 2025 | Wavewriter Alpha Prime 16 |
| Novo Nordisk INC | $17.60 | 2025 | Rybelsus, Ozempic |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.38 | 2025 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.79 | 2025 | Jardiance |
| Kowa Pharmaceuticals America, INC. | $14.62 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Elswick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.